ARTICLE | Company News

Cipla, Salix deal

October 20, 2014 7:00 AM UTC

Cipla granted Salix exclusive, worldwide rights excluding Africa and Asia, but including Japan, to patent applications covering rifaximin complexes. Cipla will receive an undisclosed upfront payment and is eligible to receive milestones and royalties. Additionally, the companies amended a 2009 deal under which Cipla granted Salix exclusive, North American rights to patents covering amorphous rifaximin. Under the amendment, the rights already licensed in North America are expanded to include patent rights in the EU, Japan, Australia, New Zealand and South Korea. Cipla declined to disclose financial details, and Salix could not be reached. ...